Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response
Status:
Active, not recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate treatment-free remission after imatinib
discontinuation in patients with chronic myeloid leukemia with deep molecular response.
Before discontinuation, patients will receive pioglitazone associated with imatinib during 3
months.